Betrixaban is a highly potent, selective, and orally efficacious factor Xa inhibitor with IC50 of 1.2 nM (inhibition of Factor 10a).

Edoxaban is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention.

5-R-Rivaroxaban is an (R) enantiomer of rivaroxaban, an oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembolic disorders.

Fondaparinux sodium is a pentasaccharide inhibitor of antithrombin-dependent factor Xa (IC50 = 40 nM). It can bind to antithrombin III.

Darexaban is a potent and orally effective factor Xa inhibitor with IC50 value of 54.6nM.

Apixaban is a direct factor Xa inhibitor with an IC50 of 0.08 nM and 0.17 nM in human and rabbit, respectively.

Rivaroxaban is an inhibitor of factor Xa (FXa) with IC50 of 0.7 nM and Ki of 0.4 nM which developed for the treatment of thrombotic disease.

Enoxaparin is one of the most commonly used low-molecular-weight heparins in a wide variety of thromboembolic disorders and has several advantages over unfractionated heparin.

Edoxaban is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention.